144 related articles for article (PubMed ID: 11180765)
21. An overview of HER2.
Lohrisch C; Piccart M
Semin Oncol; 2001 Dec; 28(6 Suppl 18):3-11. PubMed ID: 11774200
[TBL] [Abstract][Full Text] [Related]
22. [HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Mihály Z; Gyõrffy B
Magy Onkol; 2013 Sep; 57(3):147-56. PubMed ID: 24107820
[TBL] [Abstract][Full Text] [Related]
23. Unraveling the biologic and clinical complexities of HER2.
Park JW; Neve RM; Szollosi J; Benz CC
Clin Breast Cancer; 2008 Oct; 8(5):392-401. PubMed ID: 18952552
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
25. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapy in breast cancer: the HER-2/neu gene and protein.
Ross JS; Fletcher JA; Bloom KJ; Linette GP; Stec J; Symmans WF; Pusztai L; Hortobagyi GN
Mol Cell Proteomics; 2004 Apr; 3(4):379-98. PubMed ID: 14762215
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
[TBL] [Abstract][Full Text] [Related]
29. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
31. [Tykerb for breast cancer].
Suzuki Y; Saito Y; Okamura T; Tokuda Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):892-5. PubMed ID: 21677477
[TBL] [Abstract][Full Text] [Related]
32. Targeting HER2 for the treatment of breast cancer.
Rimawi MF; Schiff R; Osborne CK
Annu Rev Med; 2015; 66():111-28. PubMed ID: 25587647
[TBL] [Abstract][Full Text] [Related]
33. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
34. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
35. Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification.
Tang Y; Mackey J; Lai R; Ghosh S; Santos C; Graham K; Damaraju S; Pasdar M; Li L
J Proteomics; 2013 Oct; 91():200-9. PubMed ID: 23851309
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
38. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
[TBL] [Abstract][Full Text] [Related]
39. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
40. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
Lehr HA; Schaefer SC; Delaloye JF
Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]